NEO1 and central nervous system cancer: Multivariable analysis demonstrated that neogenin could be a beneficial factor to restrain low-grade gliomas from progressing into higher more aggressive grades that are renowned for poor clinical outcome (n = 69, p<0.01, Hazard Ratio 0.264, 95% Confidence Interval: 0.102 to 0.687, Table 3).